Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Nanologica AB ( (SE:NICA) ) has issued an update.
Nanologica AB, a Swedish life science tools company listed on Nasdaq Stockholm, focuses on advanced consumables for peptide drug purification and benefits from structural growth in diabetes and obesity treatments, while its subsidiary Syntagon provides contract manufacturing and process development for pharmaceutical raw materials. The group is now restructuring its management team following the acquisition of Syntagon, appointing Nanologica CEO Andreas Bhagwani, Syntagon CEO Annette Roos, and CFO Eva Osterman as the new group management from 1 May 2026, a move aimed at creating a more efficient leadership structure to drive sales in both operating companies and steer the group toward profitability amid its ongoing transformation and stabilized large-scale silica production.
More about Nanologica AB
Nanologica AB is a Swedish life science tools company that develops, manufactures, and sells advanced silica-based consumables to pharmaceutical manufacturers, primarily for the purification of peptide drugs such as insulin and GLP-1 analogues. Operating in a growing global niche driven by rising demand for diabetes and obesity treatments, the group also includes Syntagon, a contract manufacturer specializing in small molecule and peptide drug substances with strengths in purification and analysis of complex compounds; Nanologica is headquartered in Södertälje and its shares trade on Nasdaq Stockholm Main Market.
Average Trading Volume: 795,069
Technical Sentiment Signal: Sell
Current Market Cap: SEK350.1M
For an in-depth examination of NICA stock, go to TipRanks’ Overview page.